And expand the types of research that the company can support
Averica Discovery Services, a contract research organisation (CRO) with expertise in small molecule analysis and purification, is now able to handle Schedule I controlled substances following approval from the US Drug Enforcement Administration (DEA).
This will enhance the Marlborough, MA, US-based company's research capabilities and expand the types of research that it can support.
The DEA considers Schedule I substances to be 'the most dangerous class of drugs'. Although not generally used in a clinical setting, they are used in research in a variety of contexts. Previously, the company had been certified to work with up to Schedule II–V compounds.
Schedule I compounds have been used in research on pain, addiction, neuropsychiatry, and a variety of other human health conditions where basic research is still needed.
'A Schedule I Research registration is somewhat difficult to obtain due to the nature of the research compounds involved, and the DEA qualification and inspection is pretty involved,' said Jeffrey Kiplinger, President of Averica Discovery Services. 'This capacity allows Averica to bring its unique capabilities in analytics and purification to bear for an important segment of the industry doing valuable and necessary basic research.'